6-Nitro-4-(trifluoromethyl)-2(1H)-quinolinone is an intermediate in the synthesis of LGD-2226 (L397615), an orally active potent and selective androgen receptor modulator used in the treatment of muscle wasting and osteoporosis. Show to have an anabolic effect on muscle and bone tissue.
6-Nitro-4-trifluoromethylquinolin-2(1H)-one is obtained by nitration with 4-Trifluoromethylquinolin-2(1H)-one.
Experimental Procedure：A milky suspension of 33.0 g 4-Trifluoromethylquinolin-2(1H)-one in 200 mL H2SO4 was cooled in an ice-salt bath to -5°C. 14.3 g
70% HNO3 was added dropwise, keeping the internal temperature below 7°C. After addition
was complete, the mixture was stirred at 0-10°C for 1 h and then after removal of the ice bath
the temperature raised to room temperature within the next hours. The yellow solution was then
poured onto 600 g crushed ice and kept standing/stirring for the next 12 h. The resulting two
phases were separated and the organic phase equals a yellow slurry, which was filtered by
suction. The resulting solid was washed with water and dried under vacuum. After
crystallization of 20 g crude product in 1 L ethanol a nearly colorless solid (6-Nitro-4-trifluoromethylquinolin-2(1H)-one) (43%) was
obtained.
